Intravenous formulations of fenretinide and safingol developed by CerRx founders and the National Cancer Institute Developmental Therapeutics Program are both in early phase clinical trials. CerRx holds an exclusive license to issued patents for both of these novel formulations and issued patents covering the rights to combine them.
© CerRx, Inc. (2009-2020)